Erlotinib for frontline treatment of advanced non–small cell lung cancer: a phase II study
G Giaccone, M Gallegos Ruiz, T Le Chevalier… - Clinical Cancer …, 2006 - AACR
Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC …
[HTML][HTML] Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study
M Reck, N van Zandwijk, C Gridelli, Z Baliko… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Erlotinib is a small molecule inhibitor of epidermal growth factor receptor
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
tyrosine-kinase activity that has been shown to significantly increase survival for patients …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study
YL Wu, JH Kim, K Park, A Zaatar, G Klingelschmitt… - Lung cancer, 2012 - Elsevier
Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer
S Popat, Y Barbachano, S Ashley, A Norton, M O'Brien - Lung Cancer, 2008 - Elsevier
BACKGROUND: Both docetaxel and erlotinib improve overall survival over best supportive
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …
care in non-small cell lung cancer (NSCLC). We assessed the effectiveness of erlotinib (E) …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
[HTML][HTML] Re-administration after the failure of gefitinib or erlotinib in patients with advanced non-small cell lung cancer
Z Song, X Yu, C He, B Zhang… - Journal of Thoracic …, 2013 - ncbi.nlm.nih.gov
Objective Few treatment options are available for advanced non-small cell lung cancer
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
(NSCLC) patients who have failed of gefitinib or erlotinib treatment in second/third-line …
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
Y Wang, G Schmid-Bindert… - Therapeutic advances in …, 2012 - journals.sagepub.com
Inhibition of epidermal growth factor receptor (EGFR) has become an important target in the
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
treatment of advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib, two small …
A phase I/II study of weekly high‐dose erlotinib in previously treated patients with nonsmall cell lung cancer
DT Milton, CG Azzoli, RT Heelan… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND. Preclinical studies have suggested that erlotinib at high doses may inhibit
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
additional sites downstream of the epidermal growth factor receptor (EGFR), resulting in …
Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung …
Y Hosomi, T Seto, M Nishio, K Goto… - Thoracic …, 2022 - Wiley Online Library
Background In the phase II JO25567 study (JapicCTI‐111390), erlotinib plus bevacizumab
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …
demonstrated a significant clinical benefit in Japanese patients with epidermal growth factor …